Arkema Valuation

Is AKE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AKE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AKE (€86) is trading below our estimate of fair value (€255.47)

Significantly Below Fair Value: AKE is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AKE?

Other financial metrics that can be useful for relative valuation.

AKE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA6.7x
PEG Ratio1x

Price to Earnings Ratio vs Peers

How does AKE's PE Ratio compare to its peers?

The above table shows the PE ratio for AKE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.3x
RBT Robertet
22.6x8.0%€1.9b
ALBKK Baikowski
94.9xn/a€63.5m
SEFER SergeFerrari Group
13.4x40.9%€63.0m
NK Imerys
50.5x43.8%€2.4b
AKE Arkema
18.8x19.1%€6.4b

Price-To-Earnings vs Peers: AKE is good value based on its Price-To-Earnings Ratio (18.8x) compared to the peer average (45.3x).


Price to Earnings Ratio vs Industry

How does AKE's PE Ratio compare vs other companies in the European Chemicals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a11.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a11.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: AKE is expensive based on its Price-To-Earnings Ratio (18.8x) compared to the European Chemicals industry average (18.3x).


Price to Earnings Ratio vs Fair Ratio

What is AKE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AKE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.5x
Fair PE Ratio19.6x

Price-To-Earnings vs Fair Ratio: AKE is good value based on its Price-To-Earnings Ratio (18.8x) compared to the estimated Fair Price-To-Earnings Ratio (19.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AKE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€84.85
€107.85
+27.1%
9.9%€125.00€89.00n/a17
Oct ’25€85.80
€107.85
+25.7%
9.9%€125.00€89.00n/a17
Sep ’25€84.15
€109.50
+30.1%
9.9%€127.00€92.00n/a17
Aug ’25€85.00
€110.44
+29.9%
10.3%€127.00€92.00n/a17
Jul ’25€81.60
€111.47
+36.6%
9.3%€127.00€92.00n/a17
Jun ’25€93.75
€112.00
+19.5%
8.3%€127.00€92.00n/a16
May ’25€97.05
€110.00
+13.3%
8.4%€127.00€90.00n/a16
Apr ’25€97.54
€110.44
+13.2%
9.2%€134.00€90.00n/a16
Mar ’25€94.22
€111.88
+18.7%
8.7%€134.00€90.00n/a16
Feb ’25€100.60
€112.06
+11.4%
8.8%€134.00€90.00n/a16
Jan ’25€103.00
€111.73
+8.5%
7.7%€123.00€90.00n/a15
Dec ’24€93.04
€110.07
+18.3%
8.4%€123.00€90.00n/a15
Nov ’24€87.56
€110.40
+26.1%
8.5%€123.00€90.00n/a15
Oct ’24€93.56
€109.60
+17.1%
8.6%€125.00€90.00€85.8015
Sep ’24€97.68
€107.25
+9.8%
11.2%€125.00€85.00€84.1516
Aug ’24€96.28
€107.00
+11.1%
11.4%€125.00€85.00€85.0016
Jul ’24€86.30
€105.68
+22.5%
11.4%€123.00€82.50€81.6017
Jun ’24€82.26
€105.19
+27.9%
12.7%€130.00€82.50€93.7518
May ’24€89.62
€106.97
+19.4%
14.8%€142.00€82.50€97.0518
Apr ’24€90.80
€107.42
+18.3%
14.7%€142.00€82.50€97.5418
Mar ’24€96.24
€103.97
+8.0%
15.9%€142.00€80.00€94.2218
Feb ’24€92.88
€102.31
+10.1%
15.6%€134.00€79.00€100.6018
Jan ’24€83.88
€102.92
+22.7%
15.6%€134.00€78.00€103.0018
Dec ’23€84.20
€103.47
+22.9%
15.7%€134.00€78.00€93.0418
Nov ’23€81.04
€103.97
+28.3%
18.1%€140.00€72.00€87.5618
Oct ’23€75.08
€114.75
+52.8%
18.7%€147.00€80.00€93.5618

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies